

REMARKS

Claims 1-136 were pending prior to this Amendment. Claims 2-47, 50, 51, 70-73, 81-83, 93-95, 102-112, and 136 were previously withdrawn from consideration. In the Office Action dated December 12, 2005, the Office rejected claims 126-135 and objected to claims 1, 48, 49, 52-69, 74-80, 84-92, 96-101, and 113-125. In this Amendment, Applicants have amended claims 1, 48, 52-56, 58, 60-64, 67, 74-80, 84, 87, 90, 96-101, 113-118, 126, 130, 132, and 134, and have cancelled claims 2-47, 50, 51, 70-73, 81-83, 93-95, 102-112, 127, 128, 131, 133, and 136. Accordingly, claims 1, 48, 49, 52-69, 74-80, 84-92, 96-101, 113-126, 129, 130, 132, 134, and 135 are pending. In claim 1, X has been amended to recite only the elected moieties of Formula (II). Dependent claims 2-47 and 81-83, directed to moieties of the non-elected Formula (III) have been cancelled. Claims 60 and 74 were amended to clarify the antecedent basis.

Claim Rejections under 35 U.S.C. § 112

The Office rejected claims 126-135 under 35 U.S.C. § 112, first paragraph, as allegedly not enabled. Office Action at 2.

Solely to advance prosecution, and without acquiescence to the rejection or disclaimer of the deleted subject matter, claim 126 has been amended to recite Parkinson's disease, claim 130 has been amended to recite hypertension, and claims 132 and 134 have been amended to recite active agents selected from levodopa and prodrugs of levodopa. These amendments find support, for example, in original claims 127, 129, 131, and 133, and do not add new matter.

Applicants respectfully submit that these amendments obviate the rejection under 35 USC § 112, first paragraph, to claims 126-135 and request withdrawal of the rejection.

Claim Objections

The Office objected to claims 1, 48, 49, 52-69, 96-101, and 113-125 as allegedly being drawn to a misjoinder of invention, stating that the non-elected compounds of Groups I, II, V and VI must be cancelled. Office Action at 2.

Applicants have amended claim 48 to recite the elected compounds of Formula (Ib) and cancelled dependent claims 50-51, 70-73, 93-95, and 102-112, directed to the non-elected Formula (Ic) compounds. Applicants also cancelled non-elected independent claim 136.

Accordingly, Applicants believe the objections to the claims have obviated and removal of the objections is respectfully requested.


In view of the foregoing amendments and remarks, Applicants respectfully request reconsideration and reexamination of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: February 17, 2006

By: 

Chantal Morgan D'Apuzzo
Reg. No. 48,825
Customer No. 22,852